Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
200 participants
INTERVENTIONAL
2024-03-31
2025-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough
NCT02379637
A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
NCT04628143
Baricitinib Therapy in COVID-19
NCT04358614
A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
NCT04623021
Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients
NCT04674410
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ELIGIBILITY
Inclusion criteria:
* age 18 years and older
* participants will need daily access to use of a smartphone for at least six weeks from time of enrollment
* Positive COVID-19 test within 10 days of date of enrollment
* not already hospitalized for treatment of COVID
Exclusion criteria:
* pregnant
* already hospitalized for treatment of COVID
PROTOCOL
* 50:50 randomization: half of participants will take NAC, half will take placebo
* Participants will take NAC/placebo following this outpatient protocol:
* 2400 mg x 1 PO then
* 1200 mg PO BID x 14 days
* Participants will complete an online symptom-tracker for six weeks (daily for three weeks, weekly for three weeks)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NAC
Group receiving intervention/study drug NAC
N-acetylcysteine
N-acetylcysteine
Placebo
Group receiving placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N-acetylcysteine
N-acetylcysteine
Placebo
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* already hospitalized due to COVID
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Thoracic Foundation
UNKNOWN
Alturix
UNKNOWN
Cambridge Health Alliance
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Melisa Lai-Becker
Chief, CHA Everett Emergency Department; Director, CHA Division of Medical Toxicology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cambridge Health Alliance
Everett, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.